NASDAQ:CLNNW Clene (CLNNW) Stock Price, News & Analysis $0.03 0.00 (-2.90%) As of 05/9/2025 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About Clene Stock (NASDAQ:CLNNW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clene alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0452-Week Range$0.02▼$0.08Volume10,410 shsAverage Volume11,900 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More… Receive CLNNW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNNW Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CLNNW Stock Analysis - Frequently Asked Questions How have CLNNW shares performed this year? Clene's stock was trading at $0.05 at the beginning of the year. Since then, CLNNW shares have decreased by 39.8% and is now trading at $0.0301. View the best growth stocks for 2025 here. How do I buy shares of Clene? Shares of CLNNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLNNW CIK1822791 WebN/A Phone801-676-9695FaxN/AEmployees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$342,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:CLNNW) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.